Last reviewed · How we verify
NCT05807321
Fecobionics in Biofeedback Therapy in Dyssynergia Patients
NA trial testing Fecobionics in Dyssynergia in 24 participants. Currently enrolling.
1 January 2027
Quick facts
| Lead sponsor | The California Medical Innovations Institute, Inc. |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 24 |
| Start date | 3 October 2023 |
| Primary completion | 1 January 2027 |
| Estimated completion | 31 March 2027 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Fecobionics
Conditions studied
- Dyssynergia — all drugs for Dyssynergia →
- Constipation — all drugs for Constipation →
Sponsor
The California Medical Innovations Institute, Inc.
Who can join
Adults 21 to 75, any sex, with Dyssynergia or Constipation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Constipation affects 12-19% of Americans. Pelvic floor dyssynergia is considered to play an important role in constipation but the underlying mechanisms are not well understood in individual patients. The investigators have developed a novel device named Fecobionics that provide detailed mapping of physiological parameters during defecation. The aim of the study is to use Fecobionics to assess anorectal function in dyssynergia patients and monitor and predict the outcome of the biofeedback therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05807321
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fecobionics
Trials testing the same drug.
- NCT05412069 — Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI) · NA · recruiting
- NCT04766138 — Trial to Evaluate Fecobionics in Healthy Subjects and Patients · NA · completed
- NCT03885999 — Studies in Patients With Low Anterior Resection Syndrome (LARS) · NA · completed
- NCT03317938 — Studies in Patients With Defecatory Disorders · NA · completed
Other The California Medical Innovations Institute, Inc. trials
Trials by the same sponsor.
- NCT05412069 — Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI) · NA · recruiting
- NCT04903470 — Defecation Patterns in Constipated Patients · NA · recruiting
- NCT04766138 — Trial to Evaluate Fecobionics in Healthy Subjects and Patients · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05807321 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The California Medical Innovations Institute, Inc.
- Last refreshed: 21 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05807321.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing